Overexpression of the mitochondrial ribosomal protein S18-2 in the invasive breast carcinomas

Authors

  • L.G. Buchynska R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • N.P. Iurchenko R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • E.V. Kashuba R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • O.V. Brieieva R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • N.M. Glushchenko R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • M. Mints Department of Women’s and Children’s Health (KBH), Karolinska Institutet, Stockholm, 17176, Sweden
  • N.Yu. Lukianova R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • V.F. Chekhun R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology

Keywords:

breast cancer of luminal A and basal subtypes, mitochondrial ribosomal protein S18-2, MRPS18-2

Abstract

Summary. Background: Recent studies allow to consider the mitochondrial ribosomal protein S18-2 (MRPS18-2, S18-2) as a potential oncoprotein, which suggests the need for further characterization of its expression in tumors of different genesis including breast cancer (BC). The aim of the study was to analyze the expression of the S18-2 protein in BC of luminal A and basal subtypes. Materials and Methods: Operational material of BC patients stage І–ІІ (luminal A subtype, n = 30, and basal subtype, n = 10) was studied with the use of morphological, immunohistochemical, statistical and bioinformatic methods. Results: Using the immunohistochemical analysis, we found that the S18-2 protein showed the nuclear signal in 66.7% of luminal A subtype BC samples and 80.0% of basal subtype BC samples. The variability of the S18-2 expression in both the luminal A and basal subtypes of BC was revealed. Noteworthy, the number of cells expressing S18-2 in high-proliferating tumors of luminal A and basal subtype is significantly higher than in tumors with a low proliferative potential (p < 0.05). In 10 samples of luminal A subtype, the nuclear S18-2 signal was higher than median value. Moreover, the S18-2 protein was overexpressed in 4 out of such 10 samples. Metastases in the lymph nodes were found in 3 out of 4 patients with the stage II BC, low differentiation grade of the tumor and high proliferative activity. The bioinformatic analysis confirms our preliminary findings that the trend for increasing expression of the S18-2 protein in tumors correlates with the aggressiveness of malignant BC. Conclusion: The S18-2 protein may be a marker of cancer aggressiveness in BC patients.

References

International Agency for Research on Cancer. World Cancer Report 2014. WHO, 2014.

Fedorenko ZP, Michailovich YYo, Goulak LO, et al. Cancer in Ukraine, 2015–2016. Incidence, mortality, activities of oncological service. Bull Natl Cancer Registry of Ukraine 2017; (18). 86 p. (in Ukrainian).

Zardavas D, Irrthum A, Swanton C, Piccart M. Clinical management of breast cancer heterogeneity. Nat Rev Clin Oncol 2015; 12: 381–94.

Turashvili G, Brogi E. Tumor heterogeneity in breast cancer. Front Med 2017; 4: 227.

Ciriello G, Sinha R, Hoadley KA, et al. The molecular diversity of luminal A breast tumors. Breast Cancer Res Treat 2013; 141: 409–20.

Lehmann BD, Pietenpol JA. Clinical implications of molecular heterogeneity in triple negative breast cancer. Breast 2015; 24 (Suppl 2): 36–40.

Banin HBK, Oda JM, Losi GR, et al. Molecular markers for breast cancer: prediction on tumor behavior. Disease Markers 2014; doi: 10.1155/2014/513158.

Inoue K, Fry EA. Novel molecular markers for breast cancer. Biomark Cancer 2016; 8: 25–42.

Mints M, Mushtaq M, Iurchenko N, et al. Mitochondrial ribosomal protein S18-2 is highly expressed in endometrial cancers along with free E2F1. Oncotarget 2016; 7: 22150–8.

Mushtaq M, Jensen L, Davidsson S, et al. The MRPS18-2 protein levels correlate with prostate tumor progression and it induces CXCR4-dependent migration of cancer cells. Sci Rep 2018; 8: 2268.

Gopisetty G, Thangarajan R. Mammalian mitochondrial ribosomal small subunit (MRPS) genes: A putative role in human disease. Gene 2016; 589: 27–35.

Kashuba E, Yurchenko M, Yenamandra SP, et al. EBV-encoded EBNA-6 binds and targets MRS18-2 to the nucleus, resulting in the disruption of pRb-E2F1 complexes. Proc Natl Acad Sci USA 2008; 105: 5489–94.

Shevchuk Z, Yurchenko MY, Darekar SD, et al. Overexpression of MRPS18-2 in cancer cell lines results in appearance of multinucleated cells. Acta Naturae 2013; 5: 85–9.

Zhao H, Langerød A, Ji Y, et al. Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell 2004; 15: 2523–36.

Finak G, Bertos N, Pepin F, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 2008; 14: 518–27.

Curtis C, Shah SP, Chin SF, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012; 486: 346–52.

Downloads

Published

17.06.2023

How to Cite

Buchynska, L., Iurchenko, N., Kashuba, E., Brieieva, O., Glushchenko, N., Mints, M., … Chekhun, V. (2023). Overexpression of the mitochondrial ribosomal protein S18-2 in the invasive breast carcinomas. Experimental Oncology, 40(4), 303–308. Retrieved from https://exp-oncology.com.ua/index.php/Exp/article/view/2018-4-7

Issue

Section

Original contributions

Most read articles by the same author(s)

1 2 3 > >>